Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19086Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Tsouli, S. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T18:56:45Z | - |
| dc.date.available | 2015-11-24T18:56:45Z | - |
| dc.identifier.issn | 1389-4501 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19086 | - |
| dc.rights | Default Licence | - |
| dc.subject | Anti-Obesity Agents/administration & dosage/therapeutic use | en |
| dc.subject | Antihypertensive Agents/administration & dosage/therapeutic use | en |
| dc.subject | Body Weight/drug effects | en |
| dc.subject | Diabetes Mellitus, Type 2/*prevention & control | en |
| dc.subject | Estrogen Replacement Therapy | en |
| dc.subject | Humans | en |
| dc.subject | Hypoglycemic Agents/administration & dosage/therapeutic use | en |
| dc.subject | Hypolipidemic Agents/administration & dosage/therapeutic use | en |
| dc.subject | *Life Style | en |
| dc.subject | Risk | en |
| dc.title | Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16475962 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | BACKGROUND: Type 2 diabetes mellitus (T2DM) is a common disease that is associated with an increased risk of vascular complications. The incidence of T2DM is also increasing. It follows that T2DM prevention is important. METHODS: Relevant articles (review articles, randomised studies and large cohort and case-control studies) were identified through a Medline search (up to March 2005). RESULTS: The first trials on T2DM prevention were based on lifestyle intervention. The results of these studies were impressive since they demonstrated that even a small reduction in weight could significantly reduce the incidence of T2DM. However, the main disadvantage of lifestyle measures is that they are difficult to achieve and sustain. Therefore, pharmacological interventions have also been evaluated. The results of trials using metformin, orlistat, nateglinide, acarbose, thiazolidinediones, hormone replacement therapy, statins or fibrates are either encouraging or require more extensive evaluation. In addition, studies using antihypertensive drugs (mainly angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists) showed that these drugs could also reduce the progression to T2DM in high risk individuals. CONCLUSIONS: T2DM has major quality of life and cost implications. Therefore, more research is needed to establish safe and cost effective ways to prevent this modern epidemic. | en |
| heal.journalName | Curr Drug Targets | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
